ALGS

Aligos Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↑ 8/10
  • Value↓ 0/10
Aligos Therapeutics sales and earnings growth
ALGS Growth
Good
  • Revenue Y/Y↓ -44.59%
  • EPS Y/Y↑ 88.30%
  • FCF Y/Y↓ -2.56%
Aligos Therapeutics gross and profit margin trends
ALGS Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -1106.70%
  • ROIC 5Y↓ -282.70%
Aligos Therapeutics net debt vs free cash flow
ALGS Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -7.1

Aligos Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks